Accéder au contenu
Merck

Targeting NLRP3 and Staphylococcal pore-forming toxin receptors in human-induced pluripotent stem cell-derived macrophages.

Journal of leukocyte biology (2020-06-13)
Seong H Chow, Pankaj Deo, Amy T Y Yeung, Xenia P Kostoulias, Yusun Jeon, Mei-Ling Gao, Azadeh Seidi, Françios Alwyn Benson Olivier, Sushmita Sridhar, Cara Nethercott, David Cameron, Avril A B Robertson, Remy Robert, Charles R Mackay, Ana Traven, Zi-Bing Jin, Christine Hale, Gordon Dougan, Anton Y Peleg, Thomas Naderer
RÉSUMÉ

Staphylococcus aureus causes necrotizing pneumonia by secreting toxins such as leukocidins that target front-line immune cells. The mechanism by which leukocidins kill innate immune cells and trigger inflammation during S. aureus lung infection, however, remains unresolved. Here, we explored human-induced pluripotent stem cell-derived macrophages (hiPSC-dMs) to study the interaction of the leukocidins Panton-Valentine leukocidin (PVL) and LukAB with lung macrophages, which are the initial leukocidin targets during S. aureus lung invasion. hiPSC-dMs were susceptible to the leukocidins PVL and LukAB and both leukocidins triggered NLPR3 inflammasome activation resulting in IL-1β secretion. hiPSC-dM cell death after LukAB exposure, however, was only temporarily dependent of NLRP3, although NLRP3 triggered marked cell death after PVL treatment. CRISPR/Cas9-mediated deletion of the PVL receptor, C5aR1, protected hiPSC-dMs from PVL cytotoxicity, despite the expression of other leukocidin receptors, such as CD45. PVL-deficient S. aureus had reduced ability to induce lung IL-1β levels in human C5aR1 knock-in mice. Unexpectedly, inhibiting NLRP3 activity resulted in increased wild-type S. aureus lung burdens. Our findings suggest that NLRP3 induces macrophage death and IL-1β secretion after PVL exposure and controls S. aureus lung burdens.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-actine, clone C4, ascites fluid, clone C4, Chemicon®
Sigma-Aldrich
ATX Tris buffer, ready-to-use solution